Navigation Links
Octapharma USA Sponsors International Advisory Board for Evaluating Treatment of Patients with von Willebrand Disease
Date:6/28/2011

nts are paramount challenges. All participants were truly concerned with better controlling patient bleeding episodes and improving the quality of life for VWD patients, underscoring the need for continued scientific research."

About the Octapharma Group

Headquartered in Lachen, Switzerland, Octapharma AG is one of the largest human protein products manufacturers in the world and has been committed to patient care and medical innovation for over 27 years. Octapharma's core business is the development, production and sale of high quality human protein therapies from both human plasma and human cell-lines, including immune globulin intravenous (IGIV). In the U.S., Octapharma's IGIV product, octagam®  (immune globulin intravenous [human] 5%), is used to treat disorders of the immune system, and Octapharma's Albumin (human)® is indicated for the restoration and maintenance of circulating blood volume. Octapharma's wilate® received orphan drug exclusivity from the U.S. Food and Drug Administration (FDA) for the treatment of von Willebrand disease (VWD). Octapharma employs over 4,000 people and has biopharmaceutical experience in 80 countries worldwide, including the United States, where Octapharma USA is located in Hoboken, N.J.  Octapharma operates two state-of-the-art production sites licensed by the FDA, providing a high level of production flexibility. For more information, please visit www.octapharma.com.


'/>"/>
SOURCE Octapharma USA
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Plasma Products Safe Despite Swine Influenza Outbreak, Assures International Biopharmaceutical Company Octapharma
2. Octapharma Accepting Applications for Research Grants on Immunotherapy, Coagulation Disorders and Critical Care
3. Octapharma Targeting the Major Risk of Hemophilia Treatment - FVIII Antibodies
4. Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease
5. Octapharma Group and Fresenius Kabi Enter Into an Exclusive License, Development and Supply Agreement for a HESylated Recombinant Protein
6. Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R) - A Replacement Therapy Developed Specifically for von Willebrand Disease
7. Octapharma USA Announces Availability and Distributors for wilate®, the First Replacement Therapy Developed Specifically for von Willebrand Disease
8. FDA Confirms Orphan Drug Exclusivity Approval for wilate®, Octapharma USAs New Therapy for Common Inherited Bleeding Disorder
9. Octapharma USA Launches Web Resource for von Willebrand Disease Healthcare Professionals and Patients
10. Octapharma Accepting Applications for Research Grants Focused on Human Protein Therapies
11. Octapharma Clinical Trial Begins in the U.S. and Germany Treating Hemophilia A Patients with First Recombinant Factor VIII Derived from a Human Cell-Line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Ill., July 25, 2014 NOT FOR ... OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO ... OR REGULATIONS OF SUCH JURISDICTION AbbVie (NYSE: ABBV ... June 30, 2014. "This was another very ... per share above our original guidance and announced plans to ...
(Date:7/24/2014)... , July 24, 2014  Parnell Pharmaceuticals Holdings ... that will be added to Parnell,s already extensive ... Pty Ltd, a biotechnology company. The compounds now ... shown promise in bone regeneration and dermal regeneration, ... the compounds for the veterinary market with the ...
(Date:7/24/2014)... and MARSEILLE, France , July 24, ... global license from University of Tokyo enables development of ... gene panels, for blood cancers  Mutations of ... favorable prognosis for patients with bone marrow disorders known ... developing companion diagnostics to guide treatment with new anti-cancer ...
Breaking Medicine Technology:AbbVie Reports Second-Quarter 2014 Financial Results 2AbbVie Reports Second-Quarter 2014 Financial Results 3AbbVie Reports Second-Quarter 2014 Financial Results 4AbbVie Reports Second-Quarter 2014 Financial Results 5AbbVie Reports Second-Quarter 2014 Financial Results 6AbbVie Reports Second-Quarter 2014 Financial Results 7AbbVie Reports Second-Quarter 2014 Financial Results 8AbbVie Reports Second-Quarter 2014 Financial Results 9AbbVie Reports Second-Quarter 2014 Financial Results 10AbbVie Reports Second-Quarter 2014 Financial Results 11AbbVie Reports Second-Quarter 2014 Financial Results 12AbbVie Reports Second-Quarter 2014 Financial Results 13AbbVie Reports Second-Quarter 2014 Financial Results 14AbbVie Reports Second-Quarter 2014 Financial Results 15AbbVie Reports Second-Quarter 2014 Financial Results 16AbbVie Reports Second-Quarter 2014 Financial Results 17AbbVie Reports Second-Quarter 2014 Financial Results 18AbbVie Reports Second-Quarter 2014 Financial Results 19AbbVie Reports Second-Quarter 2014 Financial Results 20AbbVie Reports Second-Quarter 2014 Financial Results 21AbbVie Reports Second-Quarter 2014 Financial Results 22AbbVie Reports Second-Quarter 2014 Financial Results 23AbbVie Reports Second-Quarter 2014 Financial Results 24AbbVie Reports Second-Quarter 2014 Financial Results 25AbbVie Reports Second-Quarter 2014 Financial Results 26AbbVie Reports Second-Quarter 2014 Financial Results 27AbbVie Reports Second-Quarter 2014 Financial Results 28AbbVie Reports Second-Quarter 2014 Financial Results 29AbbVie Reports Second-Quarter 2014 Financial Results 30AbbVie Reports Second-Quarter 2014 Financial Results 31AbbVie Reports Second-Quarter 2014 Financial Results 32AbbVie Reports Second-Quarter 2014 Financial Results 33AbbVie Reports Second-Quarter 2014 Financial Results 34AbbVie Reports Second-Quarter 2014 Financial Results 35AbbVie Reports Second-Quarter 2014 Financial Results 36
... SAN DIEGO, Oct. 29 NuVasive, Inc. (Nasdaq: ... products for minimally disruptive surgical treatments for the spine, ... Executive Vice President, will present at the Oppenheimer 20th ... New York, New York, on Tuesday, November 3, 2009. ...
... , This holiday season, settle your stomach, relieve your wallet ... for the holidays, when many of us may suffer from occasional ... Health finds that you probably don,t need an expensive drug ... new report uses comparative effectiveness research to identify "Best Buys" based ...
Cached Medicine Technology:NuVasive to Present at the Oppenheimer 20th Annual Healthcare Conference 2NuVasive to Present at the Oppenheimer 20th Annual Healthcare Conference 3Consumer Reports Health: Americans With Heartburn Paying Too Much Green For Nexium's 'Purple Pill' 2Consumer Reports Health: Americans With Heartburn Paying Too Much Green For Nexium's 'Purple Pill' 3
(Date:7/25/2014)... July 25, 2014 (HealthDay News) -- Unlike children, the vast ... on their plate at mealtime, according to a new study. ... the world -- not just Americans, researchers from Cornell University ... to lose weight or improve their eating habits make better ... going into your stomach," researcher Brian Wansink, director of ...
(Date:7/25/2014)... Researchers at Dartmouth-Hitchcock Norris Cotton Cancer Center are exploring ... recognizes and attacks invading cancer cells. Tumors protect themselves ... as normal, even while cancer cells are dividing and ... review article published this week in WIREs Nanomedicine ... ability to fight tumors. Nanoparticles are too small ...
(Date:7/25/2014)... 2014 Innerspire, LLC ( http://www.innerspire.com ) ... as a Creative Enrollment Specialist. In this role, Greg ... as well as his accomplished design skills to further ... and to service the creative marketing needs ... work with small business owners and individuals looking to ...
(Date:7/25/2014)... July 25, 2014 “You have a brain ... 500 people and their loved ones across the U.S. every ... brain tumor diagnosis is typically met with confusion and uncertainty ... and difficult vocabulary, and make critical decisions about a course ... diagnosis is accompanied by a sense of isolation and a ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 Progress in ... in a new era of promising brain tumor treatments, ... Medical School, director of the Center for Neuro-Oncology, Dana-Farber ... (ABTA) annual Patient and Family Conference in Chicago, July ... science and new technology are impacting the development of ...
Breaking Medicine News(10 mins):Health News:Most Adults Are Members of 'Clean Plate Club' 2Health News:Scientists test nanoparticle 'alarm clock' to awaken immune systems put to sleep by cancer 2Health News:Innerspire, LLC Continues National Expansion 2Health News:Innerspire, LLC Continues National Expansion 3Health News:Innerspire, LLC Continues National Expansion 4Health News:American Brain Tumor Association to Expand Service Reach with Launch of Nationwide Volunteer Network 2Health News:American Brain Tumor Association to Expand Service Reach with Launch of Nationwide Volunteer Network 3Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 2Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 3Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 4
... Results of two separate studies show lower rates of ... and tailored interventions that may help to increase HPV ... American Association for Cancer Research Frontiers in Cancer Prevention ... Researchers at the University of California, Los ...
... Ark., Dec. 8 Many Northwest Arkansas children will get their ... Care Mobile®, the area,s first mobile dental clinic, comes to their ... the John Q. Hammons Center in Rogers, where officials spoke about ... the barriers to overall health and learning that dental disease can ...
... 8 Three in ten California households lack enough income ... released today by United Ways of California. The report ... living in California, specific to each county, for housing, food ... child care and taxes. , The complete report, ...
... ... Shepherd, Finkelman, Miller & Shah, LLP ( ... a law firm with offices in California, Connecticut, ... a lawsuit seeking class action status in the ...
... , SAN DIEGO, Dec. 8, 2009 Amylin Pharmaceuticals, Inc. (Nasdaq: ... Boston Confab on Tuesday, December 15, 2009 at 1:35 p.m. ET ... M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals, will ... and a recording will be made available following the event. The ...
... ... skin rash, anaphylactic shock, hormonal disruption and carcinogens. , It sounds crazy, ... Americans have become more careful than ever about things like the food we ... of our consumer waste, most are still at substantial risk from the cosmetic ...
Cached Medicine News:Health News:Researchers identify barriers to HPV vaccination uptake in low-income populations 2Health News:Researchers identify barriers to HPV vaccination uptake in low-income populations 3Health News:Ronald McDonald Care Mobile(R) Brings Dental Care to Area Schools 2Health News:Ronald McDonald Care Mobile(R) Brings Dental Care to Area Schools 3Health News:Ronald McDonald Care Mobile(R) Brings Dental Care to Area Schools 4Health News:New Report Finds That Three in Ten California Households Cannot Afford Basic Needs 2Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 2Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 3Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 4Health News:Shoppers Cautioned Against Poisoning With Holiday Gifts 2Health News:Shoppers Cautioned Against Poisoning With Holiday Gifts 3Health News:Shoppers Cautioned Against Poisoning With Holiday Gifts 4
... for this age group?, ,Babies and young ... of an MDI. , ,Dry powder devices ... achieve efficiency. , ,Traditional nebulizers have high ... often used for this age group are inefficient ...
... Compact Compressor is for active patients who ... and everywhere. The compressor is small and ... optionsworldwide AC compatibility (100 to 240V), 12 ... the freedom to take aerosol treatments away ...
... Compact sporty design and ... XL the product of choice ... and performance. The CompAir XL ... cord storage compartment and a ...
... The 50 psi MaxiCompressor, ... designed to run 24 hours ... week. It features a tamper-proof ... against unintentional increases or decreases ...
Medicine Products: